The MCC Administration's expertise in organization and facilitation removes obstacles and barriers to research, allowing MCC members to focus on science and translation. Under the leadership of new Associate Director for Administration, Seanne Falconer, MBA, FACHE, Administration drives the human resources, communications, community engagement, and non-science infrastructural activities necessary to achieve the mission and vision of the MCC. MCC Administration also conducts rigorous evaluations of progress towards the goals and objectives of MCC's Strategic Plan and continues to refine and improve practices and processes to provide excellent, cost-effective services, including the development of multiple grant management software/database systems. Administration includes 120 employees who provide support for the basic, clinical, and population research and educational missions of the MCC, as well as for the 229 research members from 53 UMN departments in 13 colleges. MCC collaborates across the UMN to showcase the collaborative opportunities and research resources of the MCC when recruiting faculty, resulting in the hiring of 33 new members since 2013. The MCC FY17 budget was $19.5M, including $2.3M (13%) in support from the CCSG. Recent major achievements by MCC Administration include renovating 7000 ft2 of space to accommodate new research collaborations; creating a Shared Resource Network in a mutually beneficial partnership with the Mayo Clinic Cancer Center; establishing the Community Engagement and Education Program to engage and educate communities about cancer prevention, treatment, survivorship, and clinical research; launching the Research Development Office to provide proactive services to build strategic capacity; and supporting strategic initiatives to increase solid-tumor therapeutic clinical trials accruals by 13% in 4 years. The grants administration team managed and supported the submission of 534 proposals (429 new) since 2013, totaling over $18 million in direct costs. This research portfolio includes an NCI training grant; an ACS institutional research grant; multiple U01s; and complex, multicomponent grants, including 5 P01s, a U54, and several multiple-PI, multi-institution grants. The administration revamped the pilot grant process to ensure that funding is aligned with the Strategic Plan's priorities, and implemented a return-on-investment (ROI) analysis on all pilot awards. During the previous grant period, pilot grant investments produced an ROI of 648%, converting $3.8M in pilot funding into $24.8M in cancer-focused research grants. MCC Administration was integral in the creation of the Minnesota Cancer Clinical Trials Network, which was designed to improve cancer outcomes by providing greater access to cancer clinical trials. The State legislature appropriated the initiative $4M annually, in perpetuity, and MCC immediately established a detailed budget, hired dedicated staff, convened partner organizations, defined legal contracting aspects of a statewide network, and issued an RFA to award funds to clinics throughout the state.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859349
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :
Rashidi, Armin; Shanley, Ryan; Holtan, Shernan G et al. (2018) Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:2190-2196
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891

Showing the most recent 10 out of 1013 publications